Compositions and methods for treating microbial infections

• US 8,007,817 B2
• Filed: 12/17/2009
• Issued: 08/30/2011
• Est. Priority Date: 02/13/2002
• Status: Expired due to Fees

• Current Assignee: Immunology Laboratories, Inc.
• Original Assignee: Immunology Laboratories, Inc.
• Inventors: Pillich, Jiri, Balcarek, John
• Primary Examiner(s): GRASER, JENNIFER E
• Application Number:
  US12/640,157
• Publication Number:
  US 20100158941A1
• Time in Patent Office: 621 Days
• Field of Search: None
• US Class Current: 424/243.1
• CPC Class Codes: A61K 2039/521 inactivated (killed)
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2039/543 intranasal
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/57 characterised by the type of response, e.g. Th1, Th2
• CPC Class Codes: A61K 2039/58 raising an immune response against a target which is not the antigen used for immunisation
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06
• CPC Class Codes: A61K 39/02 Bacterial antigens
• CPC Class Codes: A61K 39/0266 Klebsiella
• CPC Class Codes: A61K 39/085 Staphylococcus
• CPC Class Codes: A61K 39/092 Streptococcus
• CPC Class Codes: A61K 39/104 Pseudomonadales, e.g. Pseudomonas
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 : Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 : Antibacterial agents
• CPC Class Codes: A61P 37/04 : Immunostimulants
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 1/205 : Bacterial isolates
• CPC Class Codes: C12N 2795/00011 : Details
• CPC Class Codes: C12N 2795/00034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2795/00071 : Demonstrated in vivo effect
• CPC Class Codes: C12N 7/00 : Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: C12P 1/04 : by using bacteria
• CPC Class Codes: C12R 2001/22 : Klebsiella
• CPC Class Codes: C12R 2001/385 : Pseudomonas aeruginosa
• CPC Class Codes: C12R 2001/445 : Staphylococcus aureus

Abstract

The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.

Claims

1. A bacterial lysate derived from the infection of at least one non-pathogenic bacterial strain of Staphylococcus aureus (S. aureus) with a bacteriophage;

wherein the S. aureus bacterial strain is deposited with the CCM under accession number CCM 4992, CCM 4993, CCM 4994, CCM 4995, CCM 4996, CCM 4997, or CCM 4998; and

wherein the bacteriophage is deposited with the DSM under accession number DSM 14614, DSM 14615, or DSM 14616.

2. The bacterial lysate of claim 1 wherein the lysate is derived from the S. aureus bacterial strain having accession number CCM 4992.

3. The bacterial lysate of claim 1, wherein the lysate is derived from more than one bacterial strain deposited with the CCM under accession number CCM 4992, CCM 4993, CCM 4994, CCM 4995, CCM 4996, CCM 4997, or CCM 4998.

4. The bacterial lysate of claim 1, wherein the S. aureus bacterial strain comprises S. aureus having CCM accession number CCM 4993.

5. A method of treating pathological conditions or microbial infections in humans or animals comprising administering to a human or animal having a pathological condition a bacterial lysate derived from the infection of at least one bacterial strain of S. aureus with a bacteriophage;

wherein the S. aureus bacterial strain is deposited with the CCM under accession number CCM 4992, CCM 4993, CCM 4994, CCM 4995, CCM 4996, CCM 4997, or CCM 4998; and

wherein the bacteriophage is deposited with the DSM under accession number DSM 14614, DSM 14615, or DSM 14616.

6. The method of claim 5, wherein the bacterial lysate is administered subcutaneously, intradermally, intramuscularly, nasally, or parenterally.

7. The method of claim 6, wherein the bacterial lysate is administered nasally to the human or animal.

8. The method of claim 5, wherein the pathological condition is chronic upper respiratory disease, wound infection, osteomyelitis, endocarditis, skin polymicrobial infections, bronchial asthma, chronic sinusitis, cystic fibrosis or acne vulgaris.

9. A method of treating microbial infections comprising administering to a human or animal a bacterial lysate derived from the infection of at least one bacterial strain of S. aureus with a bacteriophage;

wherein the S. aureus bacterial strain is deposited with the CCM under accession number CCM 4992, CCM 4993, CCM 4994, CCM 4995, CCM 4996, CCM 4997, or CCM 4998; and

wherein the bacteriophage is deposited with the DSM under accession number DSM 14614, DSM 14615, or DSM 14616.

10. The method of claim 9, wherein the lysate is administered prophylactically.

11. The method of claim 9, wherein the lysate is administered three to six weeks prior to a hospitalization.

12. The method of claim 9, wherein the bacterial lysate is administered subcutaneously, intradermally, intramuscularly, nasally, or parenterally.